Who Really Decides What Gets Built in Big Pharma? The Decision-Making Architecture Behind Pharmaceutical Platform Strategy

Prepared by richstorm.co 

Key Takeaways

▸  Pharma pipeline strategy is a team sport — the CEO, CSO, BD team, and portfolio committee each play distinct roles, and getting any one wrong produces predictably poor outcomes.

▸  Therapeutic area focus decisions made quietly by CEOs are the most consequential and least reversible — a wrong call compounds negatively for an entire decade.

▸  The Head of BD is the most underappreciated role — AstraZeneca's game-changing ADC partnership was identified by the BD team, not the CEO.

▸  Companies that routinely kill weak Phase 2 programs are demonstrating better long-term capital discipline than those that advance borderline science into expensive Phase 3 failures.

▸  When evaluating any pharma company, ask four questions: Is the CEO focused on the right areas? Is the CSO identifying the right modalities early? Is BD sourcing at attractive prices? Does the portfolio committee have the courage to kill weak programs?

The Question Most Investors Never Ask

When a pharmaceutical company announces a major pipeline commitment — entering a new therapeutic area, adopting a new drug-delivery technology, or making a multi-billion dollar acquisition — the public narrative is almost always structured around the CEO. The press release quotes the CEO. The analyst calls direct questions to the CEO. The financial media attributes the decision to the CEO's vision.

This framing is both understandable and misleading. It is understandable because CEOs are the public face of companies and the accountable party for outcomes. It is misleading because the actual decisions that shape pharmaceutical pipelines are made through a complex, multi-layered governance architecture that most investors never see — and that has enormous implications for how to evaluate long-term company quality.

Understanding who really makes which decisions — and what makes each decision-maker effective or ineffective — is one of the most durable analytical advantages available to serious pharma investors. It explains why some companies consistently identify the right scientific bets early, why others repeatedly arrive late to important modality waves, and why management team quality is not captured by CEO biography alone.

Central thesis:  Pharmaceutical platform strategy is a team sport with a clear hierarchy. The CEO sets the envelope. The CSO fills it with scientific content. The BD team sources external opportunities. The portfolio committee makes capital commitment decisions. Getting any one of these roles wrong — even with a brilliant CEO — produces predictably bad outcomes.

Three Types of Platform Decisions

The first step in understanding pharmaceutical decision-making is recognizing that not all platform decisions are made the same way, by the same people, or on the same time horizon. There are three fundamentally distinct types.

Type 1 — Therapeutic Area Focus

This is the highest-level strategic decision: which diseases will the company compete in, and which will it exit? Oncology or immunology? Rare disease or primary care? Neuroscience or cardiovascular? These choices define the company's scientific identity for a decade or more.

This decision lives at the CEO level, ratified by the board. It is fundamentally a capital allocation decision dressed in scientific language. When Pascal Soriot joined AstraZeneca in 2012, he made the decision to concentrate on oncology, cardiovascular, and respiratory — and exit several other areas entirely. When Eli Lilly decided to prioritize obesity at scale alongside its diabetes franchise, that was David Ricks's strategic call.

The CSO and commercial leadership inform this decision with data — market sizing, competitive landscape, internal capability assessment. But the commitment to concentrate organizational attention and capital in specific areas is a CEO-level conviction bet. No committee produces it. No model generates it. It requires judgment about where a company's scientific heritage, financial resources, and competitive positioning can combine to create durable advantage.

Investor signal:  When a new CEO is appointed, watch the first 12 to 18 months for therapeutic area exits and entries. These are the most revealing early signals of their strategic philosophy and scientific judgment.

Type 2 — Modality Choice

Within a chosen therapeutic area, companies must decide which drug-delivery technologies and molecular mechanisms to build platforms around. Should they invest in antibody-drug conjugates or bispecific antibodies? Oral small molecules or injectable biologics? Gene therapy or RNA interference? CAR-T cell therapy or T-cell engagers?

This is where the Chief Scientific Officer has the most influence. Modality choice requires deep scientific judgment about which technologies are mature enough to build commercial platforms around, which are overhyped relative to their actual clinical potential, and which represent genuine step-changes in efficacy or convenience that will reshape treatment standards.

AstraZeneca's ADC leadership illustrates this dynamic precisely. The decision to build an ADC platform through the Daiichi Sankyo partnership was identified and architecturally designed by AZN's oncology R&D leadership before it was approved by Soriot. The scientific judgment that ADCs were the right modality — that the antibody precision combined with cytotoxic payload delivery could dramatically improve the therapeutic window in solid tumor oncology — came from the scientific organization, not from the CEO or the boardroom.

Soriot's role was to recognize the opportunity when it was presented, provide the conviction to commit capital at scale, and maintain that commitment through years of clinical development uncertainty. That is a distinct but complementary contribution — and it required enough scientific literacy to evaluate what his R&D team was telling him.

Investor signal:  Companies that consistently arrive late to important modality waves — cell therapy, ADCs, oral GLP-1 — often have CSOs who are too embedded in existing scientific expertise to advocate for genuinely disruptive new approaches. Look carefully at the CSO's background and publication record as a signal of scientific ambition versus conservatism.

Type 3 — Specific Asset Bets

The decision to advance a specific drug from Phase 2 into Phase 3 — committing $500 million to $2 billion to a single program — involves the broadest cross-functional input. The R&D team presents clinical data. The regulatory team assesses approval probability. The commercial team models market size and pricing. Business development evaluates competitive positioning. Finance models return on investment against alternative capital uses.

This process is formalized through what most large pharmaceutical companies call a Portfolio Review Committee or equivalent governance body. The committee is typically chaired by the CEO or CSO and includes the CMO, CFO, Head of Business Development, and heads of major therapeutic areas.

The committee's role is to make go/no-go decisions on specific programs and to allocate the R&D budget across the portfolio. In most well-governed companies, programs that reach the committee level have already survived earlier scientific filters — the committee is making a capital commitment decision on scientifically validated opportunities, not evaluating raw science from scratch.

The CEO's final authority in this process is real but often underestimated in scope. Very few programs are killed or advanced by CEO fiat against committee consensus. The CEO's most important role in Type 3 decisions is setting the risk tolerance that governs how the committee operates — whether it requires certainty before committing to Phase 3, or whether it is willing to advance programs with genuinely uncertain but potentially transformative Phase 2 signals.

The Full Decision Architecture

The table below maps each major type of pharmaceutical platform decision to the primary decision authority, key inputs, strategic impact, and cost of getting it wrong.

The pattern that emerges from this table is important: the highest-cost decisions are not necessarily the most visible ones. Therapeutic area focus decisions — made by CEOs and boards with relatively limited scientific input — have the most irreversible consequences. A company that misidentifies its core scientific identity and pursues the wrong therapeutic areas will carry that mistake for a decade, regardless of how well it executes operationally.

The Roles in Detail

Each function in the pharmaceutical decision architecture has a distinct contribution. The table below captures the primary function, a concrete example decision, and what makes each role genuinely effective versus merely competent.

The Most Underappreciated Role: Head of Business Development

Of all the roles in this architecture, the Head of Business Development is the most consequential for investors to understand and the most consistently underappreciated in public analysis.

In large pharmaceutical companies, the BD function is the primary mechanism through which external scientific opportunities reach the portfolio committee. BD teams constantly scan the biotech landscape, academic literature, and competitive intelligence sources for assets and platforms that could be acquired or licensed at prices that create value relative to building internally.

When AbbVie licenses ex-China rights to RemeGen's PD-1/VEGF bispecific for nearly $5 billion — that deal was identified, evaluated, and structured by the BD team before the CEO ever saw it. When Lilly acquires Verve Therapeutics for its CRISPR gene editing capabilities — the BD team identified the asset, evaluated the scientific credibility, modeled the competitive landscape, and recommended the deal. The CEO approves it; the BD team found it.

This has a critical investment implication: companies with strong BD functions can compensate effectively for gaps in internal R&D. Companies with weak BD functions miss opportunities that are visible to the entire industry. AstraZeneca's Daiichi Sankyo ADC partnership — arguably the most value-creating single business development decision in the industry over the past decade — reflects a BD team operating at an exceptionally high level.

Conversely, Pfizer's post-COVID acquisition strategy — acquiring Seagen for $43 billion, Biohaven, Arena, and Metsera in rapid succession — raises questions about BD discipline versus BD activity. Volume of deals is not a proxy for deal quality, and paying peak-cycle prices for assets in hot categories is not the same as identifying undervalued scientific opportunities early.

Investor signal:  Look for named BD leadership in proxy statements and investor day presentations. Companies that prominently feature their BD function and articulate a clear deal-sourcing philosophy are signaling organizational confidence in this critical capability.

How It Goes Wrong: Five Failure Modes

Understanding the decision architecture also explains how pharmaceutical companies make platform mistakes that are visible in hindsight but were preventable. There are five recurring failure modes.

The AstraZeneca Pre-Soriot Case Study in Failure

AstraZeneca between 2008 and 2012 is the clearest example of what happens when this architecture breaks down at the top. The company had allowed R&D investment to atrophy over a multi-year period, attempting to manage patent cliffs through cost reduction rather than pipeline building. The board and CEO of the time were prioritizing short-term financial performance over long-term scientific investment.

The result was a company entering 2012 with no credible pipeline to replace major patent expirations, profits falling 31% in a single quarter, and no strategic clarity about what kind of company it wanted to be scientifically. Soriot's appointment was essentially a board-level acknowledgment that the CEO-sets-direction function had been failing for years.

His turnaround — concentrating on three therapeutic areas, making the Daiichi Sankyo ADC bet, rejecting the Pfizer takeover — was not a series of brilliant individual decisions. It was the restoration of a functional decision-making architecture in which scientific conviction informed capital allocation rather than being subordinated to it.

The Pfizer Post-COVID Case Study in Reactive Strategy

Pfizer's post-COVID acquisition strategy represents a different failure mode: BD-driven platform building without sufficient internal scientific infrastructure to evaluate and advance what was being bought.

The Seagen acquisition for $43 billion brought ADC capabilities to Pfizer — but ADC manufacturing and clinical development expertise is not acquired through a transaction. It is built through years of organizational learning, trial and error, and scientific infrastructure investment. AstraZeneca and Daiichi Sankyo had been building that infrastructure since 2019. Pfizer acquired it in 2023 at peak valuation.

This is not necessarily a fatal mistake. The Seagen assets are real, and ADCs are a large and growing market. But it illustrates why reactive platform strategy — buying into areas after they become consensus hot — is structurally less value-creating than proactive scientific conviction built from the inside.

What This Means for Pharma Investors

The decision architecture described in this report has direct and practical implications for how investors should evaluate pharmaceutical companies.

Evaluate the Team, Not Just the CEO

CEO quality matters, but it is insufficient as the primary lens for pharmaceutical company analysis. The CSO's scientific track record, the BD team's deal history, and the CMO's regulatory experience are all inputs to a complete organizational quality assessment. Companies that consistently produce high-quality pipeline decisions across multiple CEO tenures have organizational architectures that are robust to individual leadership changes — that is a structural quality worth paying for.

Watch Portfolio Committee Decisions, Not Announcements

The most revealing signals about pharmaceutical decision-making quality come not from strategic announcements but from portfolio committee outcomes — specifically, which programs get killed and when. A company that routinely kills Phase 2 programs with honest assessments of insufficient efficacy signals is demonstrating exactly the discipline that produces good long-term capital allocation. A company that consistently advances borderline programs into Phase 3 and then fails is revealing a decision-making architecture where commercial optimism overwhelms scientific rigor.

Assess Organizational Depth After CEO Transitions

When a new CEO is appointed, the instinct is to evaluate the individual. The more important question is whether the organization beneath them — the CSO, CMO, Head of BD, and portfolio committee — has the depth to sustain the decision-making quality that produced the pipeline the new CEO is inheriting. Novo Nordisk's CEO transition illustrates this: the pipeline under Doustdar is largely the same pipeline that was under Jorgensen. The question is whether the organization can execute on it more effectively.

Treat M&A as a Diagnostic Signal

How a company does business development reveals its internal self-assessment. Companies that make targeted, scientifically precise acquisitions — buying specific capabilities that complement existing platforms — are signaling confidence in internal scientific direction. Companies that make broad, diversifying acquisitions across multiple new areas simultaneously are often signaling internal pipeline anxiety — a recognition that the organic pipeline is insufficient and that external capital deployment is substituting for internal scientific productivity.

Final framework:  When evaluating a pharmaceutical company's platform strategy, ask four questions in sequence. First, does the CEO have the scientific literacy and capital allocation discipline to set the right therapeutic area focus? Second, does the CSO have the scientific ambition to identify the right modalities before they become consensus? Third, does the BD team have the discipline to source opportunities at attractive prices rather than chasing hot areas? Fourth, does the portfolio committee have the courage to kill programs that are scientifically underwhelming regardless of how much has already been spent? A yes to all four is rare — and that rarity is why the companies that achieve it consistently outperform.

If you found this analysis useful, RichStorm publishes independent pharma investment research grounded in science. Subscribe free to receive new insights directly in your inbox. [Subscribe here]

Prepared by RichStorm LLC | May 2026 | For informational purposes only. Not investment advice. All analysis is based on publicly available information including SEC filings, company investor relations materials, earnings call transcripts, and industry publications. Past performance is not indicative of future results. RichStorm LLC is not a registered investment adviser. Readers should consult a qualified financial adviser before making investment decisions.